Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.
J Cardiol. 2013 Aug;62(2):95-101. doi: 10.1016/j.jjcc.2013.03.009. Epub 2013 May 11.
The characteristics, in-hospital management, and outcomes of patients hospitalized with worsening heart failure (HF) have been described by large-scale registries performed mainly in the USA and Europe. However, little information is available in Japan. We thus clarified the characteristics and clinical status as well as in-hospital management and outcomes among patients hospitalized with worsening HF in Japan and compared them with those reported in previous studies.
The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) studied prospectively the characteristics and treatments in patients hospitalized with worsening HF. From the total cohort of JCARE-CARD, 1677 patients were randomly selected and their detailed data during acute phase were collected as another registry database in the present study. The characteristics, in-hospital management, and outcomes were analyzed.
The mean age was 70.7 years and 59.4% were male. Etiology was ischemic in 34.0% and mean left ventricular ejection fraction was 42.5%. Carperitide was highly used as in-hospital management in Japan (33.5%) compared to the use of nesiritide in the USA (8-11%). The use of angiotensin-converting enzyme inhibitors was lower and angiotensin II receptor blockers (ARB) were more commonly used in this study compared to other studies in the USA and Europe. In-hospital crude mortality rate was comparable among studies (4-8%), however, length of stay was longer in Japan (15-20 versus 4-9 days).
The characteristics, clinical status, and laboratory data on admission in patients hospitalized with worsening HF were similar between the present study and previous Japanese and western studies. Management was also similar except for higher use of carperitide and ARB. The most striking difference between Japanese registries and those from the USA and Europe was the longer length of stay.
大型注册研究主要在美国和欧洲进行,描述了因心力衰竭恶化(HF)住院患者的特征、院内管理和结局。然而,日本的相关信息有限。因此,我们明确了日本因心力衰竭恶化住院患者的特征和临床状况以及院内管理和结局,并将其与以往研究进行了比较。
日本心脏病学心力衰竭注册研究(JCARE-CARD)前瞻性研究了因心力衰竭恶化住院患者的特征和治疗方法。从 JCARE-CARD 的总队列中,随机选择了 1677 名患者,并在本研究中收集了他们在急性阶段的详细数据作为另一个注册数据库。分析了特征、院内管理和结局。
平均年龄为 70.7 岁,59.4%为男性。病因学上,缺血性占 34.0%,平均左心室射血分数为 42.5%。与美国使用奈西立肽(8-11%)相比,在日本,卡培立肽在院内管理中被广泛使用(33.5%)。与美国和欧洲的其他研究相比,本研究中血管紧张素转换酶抑制剂的使用率较低,血管紧张素 II 受体阻滞剂(ARB)的使用率较高。住院死亡率在研究中相似(4-8%),但日本的住院时间较长(15-20 天与 4-9 天)。
本研究与以往日本和西方研究的因心力衰竭恶化住院患者的特征、入院时的临床状况和实验室数据相似。管理方法也相似,除了卡培立肽和 ARB 的使用率较高外。日本注册研究与美国和欧洲的研究之间最显著的差异是住院时间较长。